Yuhao Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuhao Cheng has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Yiqiao Hu
State Key Laboratory of Pharmaceutical Biotechnology, Medical School & School of Life Sciences, Nanjing University, Nanjing, China
4 shared publications - Jinhui Wu
Jiangsu Key Laboratory for Nano Technology, Nanjing University, Nanjing, 210093, P. R. China
3 shared publications Ahu Yuan
State Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing 210093, China
2 shared publications- Baorui Liu
Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China
1 shared publication Chenxiao Jiang
State Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing 210093, China
1 shared publicationFeng Zhi
Modern Medical Research Center, Third Affiliated Hospital of Soochow University, Changzhou 213003, China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 15 May 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (20) , eaba4311
Dissolved oxygen from microalgae-gel patch promotes chronic wound healing in diabetes
An oxygen-producing patch made from microalgae shows great potential to heal chronic wounds in diabetes.
- 15 May 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (20) , eaba4311
Top Cited PapersOpen AccessDissolved oxygen from microalgae-gel patch promotes chronic wound healing in diabetes
An oxygen-producing patch made from microalgae shows great potential to heal chronic wounds in diabetes.
- 2 May 2017
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 17 (6) , 517-526
The role of adhesions between homologous cancer cells in tumor progression and targeted therapy
Introduction: Adhesions between homologous cancer cells play an important role in promoting tumor progression and designing tumor-targeting methods. Known as ‘homologous adhesions’ of cancerous cells, these are usually more specific than adhesions to normal cells and heterogenic cells, and they have been widely discovered both in vivo and in vitro. The aberrant expression of cell adhesion-related molecules (CARMs) on each species of cancer cells is mainly responsible for inducing more specific homologous adhesions. Based on the improvement of biomimetic technologies, such adhesion has been investigated and applied deeply in drug delivery systems recently. Areas covered: This review focuses on the discovery, mechanism and application of homologous adhesion and aims to assist researchers with a clear understanding for more effective development. The advantages and challenges of recent research progress and therapeutic applications are also described and discussed. Expert commentary: Homologous adhesion shows promise in providing new strategies for targeted drug delivery and tailored cancer treatments. However, the ‘homing’ property of certain cancer cell types remains unclear and needs to be further defined.
- 2 May 2017
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 17 (6) , 517-526
The role of adhesions between homologous cancer cells in tumor progression and targeted therapy
Introduction: Adhesions between homologous cancer cells play an important role in promoting tumor progression and designing tumor-targeting methods. Known as ‘homologous adhesions’ of cancerous cells, these are usually more specific than adhesions to normal cells and heterogenic cells, and they have been widely discovered both in vivo and in vitro. The aberrant expression of cell adhesion-related molecules (CARMs) on each species of cancer cells is mainly responsible for inducing more specific homologous adhesions. Based on the improvement of biomimetic technologies, such adhesion has been investigated and applied deeply in drug delivery systems recently. Areas covered: This review focuses on the discovery, mechanism and application of homologous adhesion and aims to assist researchers with a clear understanding for more effective development. The advantages and challenges of recent research progress and therapeutic applications are also described and discussed. Expert commentary: Homologous adhesion shows promise in providing new strategies for targeted drug delivery and tailored cancer treatments. However, the ‘homing’ property of certain cancer cell types remains unclear and needs to be further defined.
- Top Cited PapersOpen Access
- 3 November 2015
- Published by Springer Nature in Nature Communications
- Vol. 6 (1) , 8785
Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy
Photodynamic therapy (PDT) kills cancer cells by converting tumour oxygen into reactive singlet oxygen (1O2) using a photosensitizer. However, pre-existing hypoxia in tumours and oxygen consumption during PDT can result in an inadequate oxygen supply, which in turn hampers photodynamic efficacy. Here to overcome this problem, we create oxygen self-enriching photodynamic therapy (Oxy-PDT) by loading a photosensitizer into perfluorocarbon nanodroplets. Because of the higher oxygen capacity and longer1O2lifetime of perfluorocarbon, the photodynamic effect of the loaded photosensitizer is significantly enhanced, as demonstrated by the accelerated generation of1O2and elevated cytotoxicity. Following direct injection into tumours,in vivostudies reveal tumour growth inhibition in the Oxy-PDT-treated mice. In addition, a single-dose intravenous injection of Oxy-PDT into tumour-bearing mice significantly inhibits tumour growth, whereas traditional PDT has no effect. Oxy-PDT may enable the enhancement of existing clinical PDT and future PDT design.
- 3 November 2015
- Published by Springer Nature in Nature Communications
- Vol. 6 (1) , 8785
Top Cited PapersOpen AccessPerfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy
Photodynamic therapy (PDT) kills cancer cells by converting tumour oxygen into reactive singlet oxygen (1O2) using a photosensitizer. However, pre-existing hypoxia in tumours and oxygen consumption during PDT can result in an inadequate oxygen supply, which in turn hampers photodynamic efficacy. Here to overcome this problem, we create oxygen self-enriching photodynamic therapy (Oxy-PDT) by loading a photosensitizer into perfluorocarbon nanodroplets. Because of the higher oxygen capacity and longer1O2lifetime of perfluorocarbon, the photodynamic effect of the loaded photosensitizer is significantly enhanced, as demonstrated by the accelerated generation of1O2and elevated cytotoxicity. Following direct injection into tumours,in vivostudies reveal tumour growth inhibition in the Oxy-PDT-treated mice. In addition, a single-dose intravenous injection of Oxy-PDT into tumour-bearing mice significantly inhibits tumour growth, whereas traditional PDT has no effect. Oxy-PDT may enable the enhancement of existing clinical PDT and future PDT design.